Perovskite precursor solution additive, perovskite solar cell and preparation method

By using quinolones or tetracycline drugs as additives in perovskite solar cells, the problems of low crystallinity and poor film formation quality of perovskite batteries are solved, and the photoelectric conversion efficiency and stability of the battery are significantly improved.

CN119031736APending Publication Date: 2024-11-26JINGLING (NANJING) ELECTRIC POWER TECHNOLOGY CO LTD
View PDF 0 Cites 1 Cited by

Patent Information

Application Number
CN202411238516.X
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-05
Publication Date
2024-11-26

AI Technical Summary

Technical Problem

The low crystallinity of perovskite solar cells, poor film formation quality and poor long-term stability are mainly due to the low coordination state of lead ions, which lead ions are prone to detachment, affecting battery performance.

Method used

Quinolones or tetracyclines are used as perovskite precursor solution additives. By coordinating with lead ions, the detachment of lead ions is inhibited, the crystal film formation quality and chemical stability are improved, and the lattice defects are passed and the energy level is adjusted. Structure, relieve interface stress and improve the overall performance of the battery.

Benefits of technology

It significantly improves the photoelectric conversion efficiency and long-term stability of perovskite solar cells, and enhances the chemical stability and comprehensive performance of the cells.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119031736A_ABST
    Figure CN119031736A_ABST
Patent Text Reader

Abstract

The invention discloses a perovskite precursor solution additive, a perovskite solar cell and a preparation method of the perovskite precursor solution additive, and a perovskite light absorption layer is prepared by adding a main component of a quinolone drug or a tetracycline drug as an additive into a perovskite precursor solution. By utilizing the principle that carboxyl, carbonyl, hydroxyl, amino and imino in quinolone and tetracycline drug component molecules are easy to coordinate with lead and tin ions, the chemical stability of perovskite crystals is improved, ion migration is inhibited, and grain boundary defects are passivated, so that the photoelectric conversion efficiency of a perovskite photovoltaic cell is improved.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the field of organic photoelectric technology, and in particular relates to a perovskite precursor solution additive, a perovskite solar cell and a preparation method thereof. Background Art

[0002] The perovskite light-absorbing layer is the core component of perovskite solar cells. Its crystal quality and film uniformity have an important influence on the comprehensive performance of the battery. At present, the perovskite light-absorbing layer material is mainly halide lead-based perovskites, such as methylamine lead iodine, formamidine lead iodine, and cesium lead iodine. Existing studies have shown that the crystallinity, film quality and stability of perovskites have an important influence on the comprehensive performance of perovskite solar cells. The crystallization and film formation of perovskite materials mainly undergo four processes, namely, the precursor solution is supersaturated to form crystal nuclei, the crystal nuclei grow into island crystals, the island crystals are connected into a network, and the network crystals continue to grow into a crystalline film. In the process of forming crystal nuclei, the low coordination state of lead ions can easily lead to low perovskite crystallinity and poor film quality. After the perovskite film is formed, the lead ions are easily removed from the lattice, causing the perovskite film to degrade and leading to poor long-term stability of the perovskite battery. Introducing additives into the perovskite precursor solution in the preparation of perovskite cells is an effective means to improve the quality of perovskite crystal film formation and inhibit the migration of lead ions. Additives can usually inhibit the escape of lead ions from the perovskite lattice by coordinating with lead ions, thereby improving the chemical stability of perovskite films. In addition, effective additives can also improve the comprehensive performance of perovskite cells by passivating lattice defects, adjusting energy level structure, relieving interface stress, and reducing the formation enthalpy of perovskite crystals. In summary, the exploration of efficient perovskite additives is an important way to improve the performance of perovskite devices. Summary of the invention

[0003] In view of the above technical problems, the primary purpose of the present invention is to provide a perovskite precursor solution additive used in the perovskite battery preparation process.

[0004] The second object of the present invention is to provide a perovskite solar cell, wherein the perovskite light absorbing layer thereof comprises the above-mentioned perovskite precursor solution additive.

[0005] The third object of the present invention is to provide a method for preparing a perovskite solar cell.

[0006] To achieve the above object, the technical solution adopted by the present invention is as follows: In a first aspect, the present invention provides a perovskite precursor solution additive, wherein the additive is added to the perovskite precursor solution, and the additive is a quinolone drug or a tetracycline drug; and the concentration of the additive is 0.05-5 mg / ml.

[0007] Preferably, the quinolone drug is one of norfloxacin, ofloxacin, levofloxacin, moxifloxacin and ciprofloxacin.

[0008] Preferably, the tetracycline drug is one of tetracycline, chlortetracycline, doxycycline and minocycline.

[0009] In a second aspect, the present invention provides a perovskite solar cell comprising a conductive glass substrate, a carrier transport layer, a perovskite light absorbing layer and a back electrode, wherein the perovskite light absorbing layer comprises an additive, and the additive is the above-mentioned perovskite precursor solution additive.

[0010] In a third aspect, the present invention provides a method for preparing a perovskite solar cell with a nip structure, comprising: Assembling an electron transport layer on the surface of the conductive glass; A perovskite precursor solution containing an additive is coated on the electron transport layer and heated to generate a perovskite light absorbing layer; the additive is the above-mentioned perovskite precursor solution additive.

[0011] A hole transport layer and a back electrode are assembled on the surface of the perovskite light absorbing layer.

[0012] Preferably, the step of coating the perovskite precursor solution containing the additive on the electron transport layer and heating the solution to generate the perovskite light absorbing layer comprises: Prepare a perovskite precursor solution with a concentration of 1-2 mol / L; adding the additive at a concentration of 0.05-5 mg / ml to the perovskite precursor solution; The perovskite precursor solution containing the additive is coated on the electron transport layer and annealed in an environment of 100-150° C. for 10-40 minutes.

[0013] In a fourth aspect, the present invention provides a method for preparing a perovskite solar cell with a pin structure, comprising: Assembling a hole transport layer or SAM layer on the surface of the conductive glass; Coating a perovskite precursor solution containing an additive on the hole transport layer or the SAM layer and heating it to generate a perovskite light absorption layer; the additive is the above-mentioned perovskite precursor solution additive; An electron transport layer and a back electrode are assembled on the surface of the perovskite light absorbing layer.

[0014] Preferably, the step of coating the perovskite precursor solution containing the additive on the hole transport layer or the SAM layer and heating the solution to generate the perovskite light absorbing layer comprises: Prepare a perovskite precursor solution with a concentration of 1-2 mol / L; adding the additive at a concentration of 0.05-5 mg / ml to the perovskite precursor solution; The perovskite precursor solution containing the additive is coated on the hole transport layer or the SAM layer, and annealed in an environment of 100-150° C. for 10-40 minutes.

[0015] Preferably, the hole transport layer is made of one of polynickel oxide, cuprous oxide, cuprous sulfide, cuprous thiocyanate, cuprous iodide, 3-hexylthiophene and 2,2',7,7'-tetrakis[N,N-di(4-methoxyphenyl)amino]-9,9'-spirobifluorene; The SAM layer includes one of [4-(3,6-dimethyl-9H-carbazole-9-yl)butyl]phosphonic acid, [2-(3,6-dimethyl-9H-carbazole-9-yl)ethyl]phosphonic acid, [4-(3,6-dimethoxy-9H-carbazole-9-yl)butyl]phosphonic acid, [4-(9H-carbazole-9-yl)butyl]phosphonic acid, [2-(3,6-dimethoxy-9H-carbazole-9-yl)ethyl]phosphonic acid and [2-(9H-carbazole-9-yl)ethyl]phosphonic acid.

[0016] Preferably, the electron transport layer uses one of [6,6]-phenyl C61 butyric acid methyl ester, [6,6]-phenyl C71 butyric acid methyl ester, footballene, SnO2, TiO2, ZnO and In2O3.

[0017] Compared with the prior art, the present invention has the following beneficial effects: The present invention uses the main components of quinolone drugs or tetracycline drugs as additives, adds them to the perovskite precursor solution, and prepares the perovskite light-absorbing layer. The principle that the carboxyl, carbonyl, hydroxyl, amino, and imine groups in the molecules of quinolone and tetracycline drug components are easily coordinated with lead and tin ions is utilized to improve the chemical stability of the perovskite crystal, inhibit ion migration, and passivate grain boundary defects, thereby improving the photoelectric conversion efficiency of the perovskite photovoltaic cell. BRIEF DESCRIPTION OF THE DRAWINGS

[0018] Figure 1 A structural diagram of a perovskite solar cell with a pin structure prepared according to an embodiment of the present invention; Figure 2 A structural diagram of a nip-structured perovskite solar cell prepared in an embodiment of the present invention; Figure 3 This is a statistical graph of the photoelectric conversion efficiency of the perovskite solar cells prepared in Example 1, Example 2, Example 3 and Comparative Example 1 of the present invention. DETAILED DESCRIPTION

[0019] The following will be combined with the drawings in the embodiments of the present invention to clearly and completely describe the technical solutions in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0020] It should be noted that, in the absence of conflict, the features in the following embodiments and implementations may be combined with each other.

[0021] If no specific conditions are specified in the examples of the present invention, the experiments were carried out under conventional conditions or conditions recommended by the manufacturer. If no manufacturer is specified for the reagents or instruments used, they are all conventional products that can be obtained by conventional technical means or purchased commercially.

[0022] In a first aspect, the present invention provides a perovskite precursor solution additive, wherein the additive is added to a perovskite precursor solution.

[0023] The additive in the present invention is an anti-inflammatory drug with a concentration of 0.05-5 mg / ml, specifically a quinolone drug or a tetracycline drug.

[0024] The perovskite precursor solution in the present invention includes but is not limited to methylamine lead iodine (MAPbI3), methylamine lead bromide (MAPbBr3), formamidine lead iodine (FAPbI3), formamidine lead bromide (FAPbBr3), cesium lead iodine (CsPbI3), cesium lead bromide (CsPbBr3), methylamine tin iodine (MASnI3), methylamine tin bromide (MASnBr3) and mixtures thereof.

[0025] Furthermore, quinolone drugs may include norfloxacin, ofloxacin, levofloxacin, moxifloxacin and ciprofloxacin.

[0026] Furthermore, tetracycline drugs may include tetracycline, chlortetracycline, doxycycline and minocycline.

[0027] In a second aspect, the present invention provides a perovskite solar cell comprising a conductive glass substrate, a carrier transport layer, a perovskite light absorbing layer and a back electrode, wherein the perovskite light absorbing layer comprises the above-mentioned perovskite precursor solution additive.

[0028] In a third aspect, the present invention provides a method for preparing a perovskite solar cell with a nip structure, the preparation process being: Step 1: ultrasonically clean the conductive glass substrate in deionized water, acetone and ethanol solutions in sequence, blow dry with nitrogen, and then treat it in a UV ozone cleaner for 10-30 minutes, and assemble the electron transport layer on the surface of the substrate by coating or evaporation.

[0029] In this step, the electron transport layer is generally a metal oxide such as SnO2, TiO2, ZnO, In2O3, etc.

[0030] Step 2: Prepare a perovskite precursor solution with a concentration of 1-2 mol / L, and add the anti-inflammatory drug ingredient norfloxacin to the solution. The concentration of norfloxacin is 0.05-5 mg / ml. The perovskite precursor solution with the anti-inflammatory drug is coated on the electron transport layer substrate and annealed at 100-150 °C for 10-40 minutes to generate a perovskite light absorbing layer.

[0031] In this step, the perovskite precursor solution includes but is not limited to methylamine lead iodine (MAPbI3), methylamine lead bromide (MAPbBr3), formamidine lead iodine (FAPbI3), formamidine lead bromide (FAPbBr3), cesium lead iodine (CsPbI3), cesium lead bromide (CsPbBr3), methylamine tin iodine (MASnI3), methylamine tin bromide (MASnBr3) and mixtures thereof.

[0032] In this step, the drug ingredient norfloxacin can be replaced by quinolone drugs such as ofloxacin, levofloxacin, moxifloxacin, ciprofloxacin, or tetracycline drugs such as tetracycline, chlortetracycline, doxycycline, and minocycline.

[0033] Step 3: Assemble the hole transport layer on the perovskite light-absorbing layer substrate and evaporate the back electrode.

[0034] In this step, the hole transport layer includes metal oxide materials such as polynickel oxide, copper oxide, copper sulfide, cuprous sulfide, and organic materials such as 3-hexylthiophene (P3HT) and 2,2',7,7'-tetrakis[N,N-di(4-methoxyphenyl)amino]-9,9'-spirobifluorene (Spiro-OMeTAD).

[0035] In a fourth aspect, the present invention provides a method for preparing a perovskite solar cell with a pin structure, the preparation process being: Step 1: ultrasonically clean the conductive glass substrate in deionized water, acetone and ethanol solutions in sequence, blow dry with nitrogen, and then treat it in a UV ozone cleaner for 10-30 min. Assemble a hole transport layer or a SAM layer on the surface of the substrate by coating or evaporation.

[0036] In this step, the hole transport layer includes inorganic materials such as polynickel oxide, cuprous oxide, cuprous sulfide, cuprous thiocyanate, cuprous iodide, and organic materials such as 3-hexylthiophene (P3HT) and 2,2',7,7'-tetrakis[N,N-di(4-methoxyphenyl)amino]-9,9'-spirobifluorene (Spiro-OMeTAD).

[0037] In this step, the SAM layer includes [4-(3,6-dimethyl-9H-carbazole-9-yl)butyl]phosphonic acid (Me-4PACz), [2-(3,6-dimethyl-9H-carbazole-9-yl)ethyl]phosphonic acid (Me-2PACz), [4-(3,6-dimethoxy-9H-carbazole-9-yl)butyl]phosphonic acid (MeO-4PACz), [4-(9H-carbazole-9-yl)butyl]phosphonic acid (4PACz), [2-(3,6-dimethoxy-9H-carbazole-9-yl)ethyl]phosphonic acid (MeO-2PACz), [2-(9H-carbazole-9-yl)ethyl]phosphonic acid (2PACz), etc.

[0038] Step 2: Prepare a perovskite precursor solution with a concentration of 1-2 mol / L, and add the anti-inflammatory drug ingredient norfloxacin to the solution. The concentration of norfloxacin is 0.05-5 mg / ml. The perovskite precursor solution with the added anti-inflammatory drug ingredient is coated on the hole transport layer substrate and annealed in an environment of 100-150 °C for 10-40 minutes.

[0039] In this step, the perovskite precursor solution includes but is not limited to methylamine lead iodine (MAPbI3), methylamine lead bromide (MAPbBr3), formamidine lead iodine (FAPbI3), formamidine lead bromide (FAPbBr3), cesium lead iodine (CsPbI3), cesium lead bromide (CsPbBr3), methylamine tin iodine (MASnI3), methylamine tin bromide (MASnBr3) and mixtures thereof.

[0040] In this step, the drug ingredient norfloxacin can be replaced by quinolone drugs such as ofloxacin, levofloxacin, moxifloxacin, ciprofloxacin, or tetracycline drugs such as tetracycline, chlortetracycline, doxycycline, and minocycline.

[0041] Step 3: Assemble the electron transport layer on the hole transport layer substrate and evaporate the back electrode.

[0042] In this step, the electron transport layer includes [6,6]-phenyl C61 butyric acid methyl ester (PC 61 BM)、[6,6]-phenyl C71 butyric acid methyl ester(PC 71 BM), football ene (C 60 ) and other organic substances and metal oxides such as SnO2, TiO2, ZnO, In2O3, etc.

[0043] The above preparation method is used to prepare nip structure perovskite solar cells and pin structure perovskite solar cells, and their performance is tested and compared with the performance of perovskite solar cells without additives. Example 1

[0044] The ITO conductive glass substrate was ultrasonically cleaned in deionized water, acetone and ethanol solutions in sequence, dried with nitrogen and then treated in a UV ozone cleaner for 10 min. The SnO2 nanocolloid solution was spin-coated on the ITO glass surface and annealed on a 150 °C hot stage for 0.5 h to obtain a SnO2 electron transport layer.

[0045] Equimolar amounts of MAI and PbI2 were dissolved in dimethyl sulfoxide (DMSO) to form a perovskite precursor solution with a concentration of 1 mol / L. Norfloxacin was added to the perovskite precursor solution with a norfloxacin concentration of 1 mg / ml. The solution was spin-coated on the substrate surface, and the speed of the coater was set to 3000 r / min. After drying for 25 seconds, 50 μl of chlorobenzene was dropped on the center of the perovskite substrate. After spin coating at 3000 r / min for 10 seconds, the ITO glass was placed on a hot plate at 120 °C and heated for 10 minutes to obtain a perovskite light-absorbing layer.

[0046] An acetonitrile solution containing 4-tert-butylpyridine (tBP) and Li-TFSI was mixed with a chlorobenzene solution of Spiro-OMeTAD and spin-coated on the perovskite light-absorbing layer substrate as a hole transport layer.

[0047] Finally, the substrate was placed in an evaporator and an 80 nm gold film was evaporated as the back electrode to prepare a nip structure perovskite solar cell. Figure 1 shown. Example 2

[0048] The ITO conductive glass was ultrasonically cleaned in deionized water, acetone and ethanol solutions in sequence, dried with nitrogen and then treated in a UV ozone cleaner for 20 min. An aqueous solution containing Sn salt colloid was spin-coated on the surface of the ITO glass and annealed on a hot stage at 180 °C for 30 min to obtain a SnO2 electron transport layer.

[0049] Equimolar amounts of FAI and PbI2 were dissolved in DMSO to form a perovskite precursor solution with a concentration of 1.2 mol / L. Levofloxacin was added to the perovskite precursor solution with a concentration of 0.5 mg / ml, and it was spin-coated on the surface of the SnO2 electron transport layer substrate. The speed of the gelling machine was set to 3000 r / min, and after drying for 15 seconds, 80 μL of chlorobenzene was dropped on the center of the perovskite substrate. After spin coating at 3000 r / min for 30 seconds, the ITO glass was placed on a 130 ℃ hot stage and heated for 10 minutes to obtain a perovskite light-absorbing layer.

[0050] An acetonitrile solution containing 4-tert-butylpyridine (tBP) and Li-TFSI was mixed with a chlorobenzene solution of Spiro-OMeTAD and spin-coated on the perovskite light-absorbing layer substrate as a hole transport layer.

[0051] Finally, the substrate was placed in an evaporator and a 70 nm gold film was evaporated as the back electrode to prepare a nip-structured perovskite solar cell. Example 3

[0052] The ITO conductive glass was ultrasonically cleaned in deionized water, acetone and ethanol solutions in sequence, dried with nitrogen and then treated in a UV ozone cleaner for 20 min. The SnO2 nanocolloid solution was spin-coated on the surface of the ITO glass and annealed on a hot stage at 140 °C for 40 min to obtain a SnO2 electron transport layer.

[0053] MAPbI3 was dissolved in sulfolane to form a perovskite precursor solution with a concentration of 1.5 mol / L. Doxycycline was added to the perovskite precursor solution, and the concentration of levodoxycycline was 2 mg / ml, and it was spin-coated on the surface of the SnO2 electron transport layer substrate. The speed of the spunbond was set to 3000 r / min, and after drying for 30 seconds, 80 μl of ethyl acetate was dropped on the center of the perovskite substrate. After spin coating at 3500 r / min for 20 seconds, the ITO glass was placed on a 110 ℃ hot stage and heated for 12 minutes.

[0054] An acetonitrile solution containing 4-tert-butylpyridine (tBP) and Li-TFSI was mixed with a chlorobenzene solution of Spiro-OMeTAD and spin-coated on the perovskite light-absorbing layer substrate as a hole transport layer.

[0055] Finally, the substrate was placed in a magnetron sputtering instrument, and an 80 nm silver film was vacuum sputtered as the back electrode to prepare a nip-structured perovskite solar cell. Example 4

[0056] The ITO conductive glass was ultrasonically cleaned in deionized water, acetone and ethanol solutions in sequence, dried with nitrogen, and then treated in a UV ozone cleaner for 20 min. The ethanol solution containing MeO-2PACz was spin-coated on the ITO glass surface and annealed on a 110 °C hot plate for 15 min to obtain a SAM layer.

[0057] FAPbI3 and CsPbBr3 were dissolved in a mixed solvent of DMF and DMSO (the molar ratio of DMF to DMSO was 1:4) at a molar ratio of 15:1 to form a perovskite precursor solution with a total molar amount of 1.5 mol / L. Norfloxacin was added to the perovskite precursor solution with a norfloxacin concentration of 1.5 mg / ml. The solution was spin-coated on the surface of the SAM layer substrate, and the speed of the coater was set to 3000 r / min. After drying for 25 seconds, 80 μL of chlorobenzene solution was dropped on the center of the perovskite substrate. After spin coating at 3000 r / min for 15 seconds, the ITO glass was placed on a hot plate at 110 °C and heated for 10 minutes to obtain a perovskite light-absorbing layer.

[0058] Will contain PC 61 The chlorobenzene solution of BM was spin-coated on the perovskite light-absorbing layer substrate as an electron transport layer.

[0059] Finally, the substrate was placed in a magnetron sputtering device and a 100 nm silver film was vacuum sputtered as the back electrode. A pin structure perovskite solar cell was prepared, such as Figure 2 shown. Example 5

[0060] The ITO conductive glass was ultrasonically cleaned in deionized water, acetone and ethanol solutions in turn, dried with nitrogen, and then treated in a UV ozone cleaner for 25 min. A uniform solution of water and isopropanol (molar ratio of water to isopropanol was 4:1) containing polynickel oxide was spin-coated on the surface of the ITO glass and annealed on a hot plate at 180 °C for 30 min to obtain a hole transport layer.

[0061] FAPbIr3 and CsPbI3 were dissolved in a mixed solvent of DMF and DMSO (the molar ratio of DMF to DMSO was 1:4) at a molar ratio of 12:1 to form a perovskite precursor solution with a total molar weight of 1.4 mol / L. Chlortetracycline was added to the perovskite precursor solution with a concentration of 3 mg / ml, and it was spin-coated on the surface of the hole transport layer substrate. The speed of the sizing machine was set to 4000 r / min, and after drying for 25 seconds, 120 μL of chlorobenzene solution was dropped on the center of the perovskite substrate. After spin coating at 4000 r / min for 15 seconds, the ITO glass was placed on a 150 °C hot plate and heated for 15 minutes to obtain a perovskite light-absorbing layer.

[0062] Will contain PC 61 The chlorobenzene solution of BM was spin-coated on the perovskite light-absorbing layer substrate as an electron transport layer.

[0063] Finally, the substrate was placed in a magnetron sputtering instrument, and an 80 nm silver film was vacuum sputtered as the back electrode to prepare a pin-structured perovskite solar cell.

[0064] Comparative Example 1 (without high-efficiency additive) Comparative Example 1 is a comparative example of the above-mentioned Example 1, except that no additive is prepared in the perovskite light-absorbing layer of Comparative Example 1, and the rest of the preparation process is the same as that of the above-mentioned Example 1, and the preparation process is as follows: The ITO conductive glass was ultrasonically cleaned in deionized water, acetone and ethanol solutions in sequence, dried with nitrogen and then treated in a UV ozone cleaner for 10 min. The SnO2 nanocolloid solution was spin-coated on the surface of the ITO glass and annealed on a hot plate at 150 °C for 0.5 h to obtain a SnO2 electron transport layer.

[0065] Equimolar amounts of MAI and PbI2 were dissolved in DMSO to form a solution with a concentration of 1 mol / L, and the solution was spin-coated on the surface of the SnO2 electron transport layer substrate. The speed of the coater was set to 3000 r / min. After drying for 25 seconds, 50 μl of chlorobenzene was dropped on the center of the perovskite substrate. After spin coating at 3000 r / min for 10 seconds, the ITO glass was placed on a 120 °C hot stage and heated for 10 minutes to obtain the perovskite light-absorbing layer.

[0066] An acetonitrile solution containing 4-tert-butylpyridine (tBP) and Li-TFSI was mixed with a chlorobenzene solution of Spiro-OMeTAD and spin-coated on a perovskite substrate as a hole transport layer.

[0067] Finally, the substrate was placed in an evaporator and an 80 nm gold film was evaporated as the back electrode to prepare a nip-structured perovskite solar cell.

[0068] The perovskite solar cells prepared in the above-mentioned Examples 1 to 3 and Comparative Example 1 were tested to obtain the IV test curves of the prepared perovskite solar cells, and the photoelectric conversion efficiency was calculated. Figure 3 It can be seen that the efficiency of the cells prepared in Examples 1-3 is significantly higher than that in Comparative Example 1. Therefore, the use of the high-efficiency additives described in the present invention to prepare perovskite cells can improve the photoelectric conversion efficiency of the cells.

[0069] Those skilled in the art will readily appreciate other embodiments of the present application after considering the specification and practicing the contents disclosed herein. The present application is intended to cover any variations, uses or adaptations of the present application, which follow the general principles of the present application and include common knowledge or customary technical means in the art that are not disclosed in the present application.

[0070] It should be understood that the present application is not limited to the exact construction that has been described above and shown in the drawings, and that various modifications and changes may be made without departing from the scope thereof.

Claims

1. A perovskite precursor solution additive, characterized in that: The additive is added to the perovskite precursor solution, and the additive is a quinolone drug or a tetracycline drug; the concentration of the additive is 0.05-5 mg / ml.

2. The perovskite precursor solution additive according to claim 1, characterized in that: The quinolone drug is one of norfloxacin, ofloxacin, levofloxacin, moxifloxacin and ciprofloxacin.

3. The perovskite precursor solution additive according to claim 1, characterized in that: The tetracycline drug is one of tetracycline, chlortetracycline, doxycycline and minocycline.

4. A perovskite solar cell, comprising a conductive glass substrate, a carrier transport layer, a perovskite light absorbing layer and a back electrode, characterized in that: The perovskite light-absorbing layer includes an additive, and the additive is the perovskite precursor solution additive according to any one of claims 1 to 3.

5. A method for preparing a perovskite solar cell, characterized in that: include: Assembling an electron transport layer on the surface of the conductive glass; Applying a perovskite precursor solution containing an additive to the electron transport layer and heating it to generate a perovskite light absorbing layer; The additive is the perovskite precursor solution additive according to any one of claims 1 to 3; A hole transport layer and a back electrode are assembled on the surface of the perovskite light absorbing layer.

6. The method for preparing a perovskite solar cell according to claim 5, characterized in that: The method of coating the perovskite precursor solution containing the additive on the electron transport layer and heating the solution to generate the perovskite light absorbing layer comprises: Prepare a perovskite precursor solution with a concentration of 1-2 mol / L; adding the additive at a concentration of 0.05-5 mg / ml to the perovskite precursor solution; The perovskite precursor solution containing the additive is coated on the electron transport layer and annealed in an environment of 100-150° C. for 10-40 minutes.

7. A method for preparing a perovskite solar cell, characterized in that: include: Assembling a hole transport layer or SAM layer on the surface of the conductive glass; Coating a perovskite precursor solution containing an additive on the hole transport layer or the SAM layer and heating it to generate a perovskite light absorption layer; the additive is the perovskite precursor solution additive according to any one of claims 1 to 3; An electron transport layer and a back electrode are assembled on the surface of the perovskite light absorbing layer.

8. The method for preparing a perovskite solar cell according to claim 7, characterized in that: The method of coating the perovskite precursor solution containing the additive on the hole transport layer or the SAM layer and heating the solution to generate the perovskite light absorbing layer comprises: Prepare a perovskite precursor solution with a concentration of 1-2 mol / L; adding the additive at a concentration of 0.05-5 mg / ml to the perovskite precursor solution; The perovskite precursor solution containing the additive is coated on the hole transport layer or the SAM layer, and annealed in an environment of 100-150° C. for 10-40 minutes.

9. The method for preparing a perovskite solar cell according to claim 7, characterized in that: The hole transport layer is made of one of polynickel oxide, cuprous oxide, cuprous sulfide, cuprous thiocyanate, cuprous iodide, 3-hexylthiophene and 2,2',7,7'-tetrakis[N,N-di(4-methoxyphenyl)amino]-9,9'-spirobifluorene; The SAM layer adopts one of [4-(3,6-dimethyl-9H-carbazole-9-yl)butyl]phosphonic acid, [2-(3,6-dimethyl-9H-carbazole-9-yl)ethyl]phosphonic acid, [4-(3,6-dimethoxy-9H-carbazole-9-yl)butyl]phosphonic acid, [4-(9H-carbazole-9-yl)butyl]phosphonic acid, [2-(3,6-dimethoxy-9H-carbazole-9-yl)ethyl]phosphonic acid and [2-(9H-carbazole-9-yl)ethyl]phosphonic acid.

10. The method for preparing a perovskite solar cell according to claim 7, characterized in that: The electron transport layer adopts one of [6,6]-phenyl C61 butyric acid methyl ester, [6,6]-phenyl C71 butyric acid methyl ester, octylene, SnO2, TiO2, ZnO and In2O3.

Citation Information

Cited By

  • Perovskite thin film preparation method based on 3, 3 '-thiodipropionic acid pre-coordination regulation and control, perovskite thin film and perovskite solar cell

    CN122421644A